Requests · The University of Texas Health Science Center at San Antonio

T3: Translational Therapeutics for Texas

Priority 2 · one of 3 items in the The University of Texas Health Science Center at San Antonio's request for 2028-29 · The item begins on page 109 of the request

This is a request, not an appropriation.

What is asked

20282029Two years
All funds$12,500,000$12,500,000$25,000,000
Of which general revenue and general revenue-dedicated $12,500,000$12,500,000$25,000,000
Positions (full-time equivalents) 12.015.0

How it would be financed

Method of financing, as the request prints it20282029
1 General Revenue Fund$12,500,000$12,500,000
Total, as the request prints it$12,500,000$12,500,000

Where it would land

The strategies this item would add to, numbered as the request numbers them, beside what each is appropriated in the current budget (2026-27 Act). One column is an appropriation and the other a request made on top of a base request not shown here, so the two are not subtracted.

Strategy Asked 2028Asked 2029Positions Appropriated 2026Appropriated 2027
05-04-01 Exceptional Item Request $12,500,000$12,500,00015.0No strategy matched in the current budget

A strategy is matched by its name. Where none is matched, the strategy may be new, or may be in the current budget under a different name.

After 2029

The agency's estimate203020312032Three years
All funds$12,500,000$12,500,000$12,500,000$37,500,000
Of which general revenue$12,500,000$12,500,000$12,500,000$37,500,000

In the agency's words: FY2028-32 costs are recurring: regulatory/IND, shared-facility and staff, faculty recruitments/retention. Instrument acquisition planned in FY2028-29; instrumentation costs shift in FY2030 to service contracts, maintenance, and phased replacement.

The agency's justification

UT Health Science Center San Antonio is uniquely poised to deliver a groundbreaking drug-development initiative, Translational Therapeutics for Texas (T3), designed to turn university discoveries into investigational new drugs (INDs) -- the treatments cleared to enter human clinical trials -- for Texas patients. T3 targets diseases that burden Texans: cancer, including childhood and pancreatic cancers; Alzheimer's disease; and disorders of pain, addiction, and mental health. Building on the Health Science Center's NCI-designated cancer center, a CPRIT- and NCI-supported drug-discovery center (CIDD), and strong pharmacology and structural biology programs, T3 will move new medicines from laboratory discovery toward the clinic. This directly advances the national Genesis Mission and its NIH-led Bio Genesis Mission (July 2026), which commit federal funding to speed drug discovery and aim to halve the time it takes for discoveries to reach patients, positioning Texas to compete for that investment. Beyond improving lives, T3 keeps the resulting intellectual property, companies, jobs, and clinical activity in Texas, strengthening the state's economy and life-sciences industry. This request supports four senior scientist faculty recruits across the Departments of Pharmacology and Biochemistry and Structural Biology, support staff, a regulatory team that prepares medicines for FDA review, and shared instrumentation for structural biology, mass spectrometry, and pharmacology.

External and internal factors

Internally, the September 2025 merger that brought together UT Health Science Center San Antonio and UT San Antonio placed under one institution a unique array of capabilities bringing together most elements of a drug-development pipeline. The translational instrumentation and faculty this request provides are the principal remaining gap. The institution is planning to invest $65 million through its Nexus Initiative in multi- omics and AI-informed high-performance computing; because those investments cannot pay for faculty or operations, this request funds what they cannot. T3 is deliberately complementary to existing Texas capability, which is concentrated in oncology. It extends drug development into broader diseases impacting Texans, drawing on one of the nation's largest early-phase trial programs. San Antonio adds a partner ecosystem no other Texas metro matches: Southwest Research Institute, Texas Biomedical Research Institute, UT San Antonio, the 900-acre South Texas Medical Center, and a large military medical community. Institutional master planning includes a Discovery Park to host industry partners and start-ups. Externally, drug discovery is a declared national priority: the July 2026 Genesis and Bio Genesis Missions direct billions toward AI-enabled discovery. Competition for scientists is intense.

As marked in the request